HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), announced plans to acquire Dura Medical as its first Florida acquisition. Dura Medical, founded in 2018 with clinics in Naples and Fort Myers, provides interventional psychiatry services including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, and Spravato®.
The acquisition is expected to be immediately accretive to revenue and EBITDA for NRx. Dura's founder, Stephen Durand, will serve as HOPE's Director of Clinical Growth for Florida. The company partners with the Veterans Affairs Community Cares Network, ensuring veterans have access to treatment for mental health conditions.
Dura Medical aims to treat more than 10,000 people by 2026. The acquisition is subject to financing, financial audits, definitive agreements, and standard closing conditions.
HOPE Therapeutics, una sussidiaria di NRx Pharmaceuticals (NASDAQ: NRXP), ha annunciato piani per acquisire Dura Medical come prima acquisizione in Florida. Dura Medical, fondata nel 2018 con cliniche a Napoli e Fort Myers, offre servizi di psichiatria interventistica tra cui la terapia con infusione di ketamina, la stimolazione magnetica transcranica e Spravato®.
Si prevede che l'acquisizione porterà immediatamente un incremento di fatturato e EBITDA per NRx. Il fondatore di Dura, Stephen Durand, assumerà il ruolo di Direttore della Crescita Clinica per la Florida presso HOPE. L'azienda collabora con la Veterans Affairs Community Cares Network, assicurando ai veterani l'accesso ai trattamenti per le condizioni di salute mentale.
Dura Medical mira a trattare oltre 10.000 persone entro il 2026. L'acquisizione è soggetta a finanziamenti, audit finanziari, accordi definitivi e condizioni standard di chiusura.
HOPE Therapeutics, una subsidiaria de NRx Pharmaceuticals (NASDAQ: NRXP), anunció planes para adquirir Dura Medical como su primera adquisición en Florida. Dura Medical, fundada en 2018 con clínicas en Naples y Fort Myers, proporciona servicios de psiquiatría intervencionista que incluyen terapia de infusión de ketamina, estimulación magnética transcraneal y Spravato®.
Se espera que la adquisición sea inmediatamente rentable para los ingresos y EBITDA de NRx. El fundador de Dura, Stephen Durand, servirá como Director de Crecimiento Clínico de HOPE para Florida. La compañía colabora con la red de cuidados comunitarios del Departamento de Asuntos de Veteranos, asegurando que los veteranos tengan acceso a tratamientos para condiciones de salud mental.
Dura Medical tiene como objetivo tratar a más de 10,000 personas para 2026. La adquisición está sujeta a financiamiento, auditorías financieras, acuerdos definitivos y condiciones estándar de cierre.
HOPE Therapeutics는 NRx Pharmaceuticals (NASDAQ: NRXP)의 자회사로, 플로리다에서의 첫 번째 인수로 Dura Medical를 인수할 계획을 발표했습니다. Dura Medical은 2018년에 설립되어 네이플스와 포트 마이어스에 클리닉을 운영하고 있으며, 케타민 주입 치료, 경두개 자극 치료 및 Spravato®를 포함한 개입 정신과 서비스를 제공합니다.
이번 인수는 NRx의 수익과 EBITDA에 즉각적인 기여를 할 것으로 예상됩니다. Dura의 창립자인 Stephen Durand는 HOPE의 플로리다 지역 임상 성장 이사로 임명될 것입니다. 이 회사는 재향군인 관리 커뮤니티 케어 네트워크와 협력하여 재향군인들이 정신 건강 치료를 받을 수 있도록 보장합니다.
Dura Medical은 2026년까지 10,000명 이상을 치료하는 것을 목표로 하고 있습니다. 이번 인수는 자금 조달, 재무 감사, 구체적인 계약 및 표준 마감 조건에 따라 이루어질 예정입니다.
HOPE Therapeutics, une filiale de NRx Pharmaceuticals (NASDAQ: NRXP), a annoncé des projets d'acquisition de Dura Medical en Floride, qui sera sa première acquisition dans cet État. Dura Medical, fondée en 2018 avec des cliniques à Naples et Fort Myers, offre des services de psychiatrie interventionnelle, notamment la thérapie par infusion de kétamine, la stimulation magnétique transcrânienne et Spravato®.
On s'attend à ce que cette acquisition soit immédiatement positive pour les revenus et l'EBITDA de NRx. Le fondateur de Dura, Stephen Durand, occupera le poste de directeur de la croissance clinique pour la Floride au sein d'HOPE. L'entreprise collabore avec le réseau de soins communautaires des vétérans, garantissant ainsi l'accès des vétérans à des traitements pour des troubles de santé mentale.
Dura Medical vise à traiter plus de 10 000 personnes d'ici 2026. L'acquisition est soumise à un financement, des audits financiers, des accords définitifs et des conditions de clôture standard.
HOPE Therapeutics, eine Tochtergesellschaft von NRx Pharmaceuticals (NASDAQ: NRXP), gab Pläne zur Übernahme von Dura Medical als erste Übernahme in Florida bekannt. Dura Medical, gegründet im Jahr 2018 mit Kliniken in Naples und Fort Myers, bietet interventionelle psychiatrische Dienstleistungen an, darunter Ketamin-Infusionstherapie, transkranielle Magnetstimulation und Spravato®.
Die Übernahme wird voraussichtlich sofortige positive Auswirkungen auf den Umsatz und das EBITDA von NRx haben. Der Gründer von Dura, Stephen Durand, wird als Direktor für klinisches Wachstum von HOPE in Florida tätig sein. Das Unternehmen arbeitet mit dem Veterans Affairs Community Cares Network zusammen, um sicherzustellen, dass Veteranen Zugang zu Behandlungen für psychische Erkrankungen haben.
Dura Medical plant, bis 2026 mehr als 10.000 Menschen zu behandeln. Die Übernahme unterliegt der Finanzierung, finanziellen Prüfungen, endgültigen Verträgen und den üblichen Abschlussbedingungen.
- Acquisition expected to be immediately accretive to revenue and EBITDA
- Established presence in Florida market with two operational clinics
- Revenue generating and EBITDA positive business
- Immediate expansion opportunity to Florida's East Coast
- Access to Veterans Affairs Community Cares Network partnership
- Acquisition subject to financing and other conditions
- Non-binding Letter of Intent - deal not yet finalized
Insights
This planned acquisition marks a strategic entry into Florida's interventional psychiatry market. Dura Medical brings immediate value through its revenue-generating, EBITDA-positive operations and established presence in Naples and Fort Myers. The deal structure shows promise with Dura's founder stepping into a leadership role for regional expansion, suggesting strong post-merger integration potential.
The target's VA CCN partnership is particularly valuable, providing stable revenue streams through government contracts. The mental health market opportunity is substantial, with 13 million Americans considering suicide annually. Given NRXP's micro-cap status (
The acquisition targets a critical gap in mental healthcare delivery. Dura's comprehensive treatment portfolio, including Ketamine Infusion Therapy, TMS and Spravato®, positions it at the forefront of interventional psychiatry. The veteran focus is particularly strategic, addressing a high-need population with established reimbursement pathways.
The expansion plan to Florida's East Coast indicates strong market opportunity in a state with significant mental health needs. The clinic's ambitious goal to treat 10,000 patients by 2026 suggests substantial growth potential, especially with HOPE's corporate infrastructure support. The integration of traditional psychiatry with innovative treatments creates a compelling full-service model that could set industry standards.
- Dura Medical, with initial clinics in
Naples andFort Myers , to anchor the HOPE network inFlorida - Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of
Florida - Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in
Florida - Acquisition expected to be immediately accretive to revenue and EBITDA for NRx
Dura was founded in 2018 to offer a gold-standard, precision approach to treating mental health and chronic pain. The clinics were the first in
As a US Army Veteran, Mr. Durand and Dura Medical are proud to partner with the Veterans Affairs Community Cares Network (VA CCN) which ensures that military veterans have full access to treatment for suicidal depression, PTSD, and Traumatic Incident Reduction (TIR).
In conjunction with the planned acquisition, Mr. Durand has agreed to serve as HOPE's Director of Clinical Growth for
"Dura Medical was founded with the mission to reduce suicide in our community and aims to treat more than 10,000 people by 2026. We're excited to accelerate that mission by joining the HOPE Network and leading HOPE's expansion in
"We are delighted to welcome Dura to the HOPE family and look forward to working together to grow both Dura and the HOPE
The intended acquisition of Dura is subject to obtaining necessary financing, the completion of financial audits, execution of definitive agreements, and the satisfaction of standard closing conditions.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
1 https://www.cdc.gov/suicide/facts/data.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaq-nrxp-announce-dura-medical-as-the-expected-initial-florida-acquisition-for-its-planned-international-network-of-interventional-psychiatry-clinics-302342666.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the expected financial impact of Dura Medical acquisition on NRXP?
How many clinics will NRXP acquire through the Dura Medical acquisition?
What services does Dura Medical offer that NRXP will acquire?
What is Dura Medical's treatment goal by 2026 under NRXP ownership?
What conditions must be met for NRXP to complete the Dura Medical acquisition?
